

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/521,071	12/02/2005	Sai Kiang Lim	084330-000000US	5425	
24197	7590 09/01/2006		EXAM	EXAMINER	
KLARQUIST SPARKMAN, LLP			KIM, TAEYOON		
121 SW SALMON STREET SUITE 1600 PORTLAND, OR 97204			ART UNIT	PAPER NUMBER	
		•	1651	1651 DATE MAILED: 09/01/2006	
			DATE MAILED: 09/01/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		10/521,071	LIM, SAI KIANG			
		Examiner	Art Unit			
		Taeyoon Kim	1651			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
2a) <u></u> □	Responsive to communication(s) filed on This action is FINAL . 2b) This Since this application is in condition for allowan closed in accordance with the practice under <i>E</i>	- action is non-final. ice except for formal matters, p				
Dispositi	on of Claims					
5)☐ 6)☐ 7)☐ 8)⊠ Applicati 9)☐ 10)☐	Claim(s) 15-28 is/are pending in the application 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 15-28 are subject to restriction and/or on Papers The specification is objected to by the Examiner The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examiner The oath or declaration is objected to by	election requirement. c. epted or b) objected to by the drawing(s) be held in abeyance. So on is required if the drawing(s) is constant.	See 37 CFR 1.85(a). Objected to. See 37 CFR 1.121(d).			
	inder 35 U.S.C. § 119		707.			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
2) 🔲 Notice 3) 🔲 Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	4) Interview Summa Paper No(s)/Mail 5) Notice of Informal 6) Other:				

Art Unit: 1651

DETAILED ACTION

Claims 15-28 are pending.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 15-18, drawn to a purified preparation of mammalian hemangioblast cells.

Group II, claims 19-22, drawn to a method of preparing a mammalian hemangioblast cell line.

Group III, claim 23, drawn to a hemangioblast cell line.

Group IV, claims 24-26, drawn to a method of using mammalian/human hemangioblast cells.

Group V, claim 27, drawn to a method of delivering a therapeutic gene to a patient.

Group VI, claim 28, drawn to a commercial package containing human hemangioblast cells.

(a) An international or national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept. Where a

Page 3

Art Unit: 1651

group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those invention involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

- (b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:
 - a product and a process specially adapted for the manufacture of said product; or
 - (2) a product and a process of use of said product; or
 - (3) a product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
 - (4) a process and an apparatus or means specifically designed for carrying out said process; or
 - (5) a product, a process specially adapted for the manufacture of the said product and an apparatus or means specifically designed for carrying out said process.
- (c) If an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present.

The groups of invention fall within category (2), a product and a method of use of that product.

PCT Rule 13.2 does not provide for multiple compositions or multiple methods of use within a single application. Thus, the first appearing composition is combined with a corresponding first method of use and the additional composition and method claims each constitute a separate group.

In addition to the requirement that a group of inventions must belong to one of the specific categories provided by PCT Rule 13.2, the inventions in the category, such as a composition and a method of use of the composition, must have a special technical feature that unites them. See Patent Rules 1.475, where a special technical feature is a contribution OVER THE PRIOR ART.

Thus, the inventions listed as Groups I-V and VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features as demonstrated above. Since the composition, hemangioblast cells, is known in the art, see Lacaud et al. (Ann. N.Y. Acad. Sci. 2001), no special technical feature unites these inventions in a category.

The expression "special technical feature" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art (PCT Rule 13.2). Thus, a feature found in the prior art cannot be considered to be a special technical feature.

Art Unit: 1651

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taeyoon Kim whose telephone number is 571-272-9041. The examiner can normally be reached on 8:00 am - 4:30 pm ET (Mon-Fri).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Taeyoon Kim Patent Examiner Art Unit 1651 Leon B Lankford, Ur Primary Examiner Art Unit 1651